Completed
OBSERVATIONAL
NCT05701007
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
Interventions
Name:
abiraterone
Type:
DRUG
Description:
mCRPC
Name:
enzalutamide
Type:
DRUG
Description:
mCRPC
Name:
docetaxel
Type:
DRUG
Description:
mCRPC
Name:
apalutamide
Type:
DRUG
Description:
mCRPC
Name:
cabazitaxel
Type:
DRUG
Description:
mCRPC
Name:
Radium-223
Type:
DRUG
Description:
mCRPC
Name:
Lutetium-177
Type:
DRUG
Description:
mCRPC
Name:
degarelix
Type:
DRUG
Description:
mCSPC
Name:
goserelin
Type:
DRUG
Description:
mCSPC
Name:
leuprorelin
Type:
DRUG
Description:
mCSPC
Name:
triptorelin
Type:
DRUG
Description:
mCSPC
Primary Outcomes
Measure:
Characteristics of Metastatic Cancer Patients
TimeFrame:
up to 12 years
Description:
Demographical and clinical variables of patients will be summarized
Measure:
Number of treatments received for metastatic prostate cancer
TimeFrame:
up to 12 years
Description:
Measure:
Overall Survival (OS)
TimeFrame:
up to 12 years
Description:
Measure:
Time to next treatment (TTNT)
TimeFrame:
up to 12 years
Description:
Trial Information
NCT ID
NCT05701007
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Pfizer
Last Updated
December 15, 2025